Royalty Pharma plc (NASDAQ: RPRX) open the trading on Wednesday, with a bit cautious approach as it glided -0.36% to $39.25, before settling in for the price of $39.39 at the close. Taking a more long-term approach, RPRX posted a 52-week range of $25.01-$41.24.
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was -21.51%. Meanwhile, its Annual Earning per share during the time was -21.51%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 10.57%. This publicly-traded company’s shares outstanding now amounts to $429.03 million, simultaneously with a float of $336.38 million. The organization now has a market capitalization sitting at $22.66 billion. At the time of writing, stock’s 50-day Moving Average stood at $38.48, while the 200-day Moving Average is $35.57.
Royalty Pharma plc (RPRX) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Royalty Pharma plc’s current insider ownership accounts for 21.30%, in contrast to 79.76% institutional ownership. According to the most recent insider trade that took place on Dec 19 ’25, this organization’s EVP, Research & Investments sold 20,000 shares at the rate of 38.38, making the entire transaction reach 767,582 in total value, affecting insider ownership by 120,000. Preceding that transaction, on Dec 17 ’25, Company’s EVP, Investments & CLO sold 79,346 for 38.57, making the whole transaction’s value amount to 3,060,280. This particular insider is now the holder of 30,654 in total.
Royalty Pharma plc (RPRX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.15 per share during the current fiscal year.
Royalty Pharma plc’s EPS increase for this current 12-month fiscal period is 10.57% and is forecasted to reach 4.78 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 8.48% through the next 5 years, which can be compared against the -21.51% growth it accomplished over the previous five years trading on the market.
Royalty Pharma plc (NASDAQ: RPRX) Trading Performance Indicators
Let’s observe the current performance indicators for Royalty Pharma plc (RPRX). It’s Quick Ratio in the last reported quarter now stands at 3.48. Alongside those numbers, its PE Ratio stands at $22.44, and its Beta score is 0.42. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 9.64. Similarly, its price to free cash flow for trailing twelve months is now 9.03.
In the same vein, RPRX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 1.75, a figure that is expected to reach 1.27 in the next quarter, and analysts are predicting that it will be 4.78 at the market close of one year from today.
Technical Analysis of Royalty Pharma plc (RPRX)
[Royalty Pharma plc, RPRX] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 90.71% While, its Average True Range was 58.02.
Raw Stochastic average of Royalty Pharma plc (RPRX) in the period of the previous 100 days is set at 72.20%, which indicates a major rise in contrast to 69.27% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.72 that was lower than 0.85 volatility it exhibited in the past 100-days period.
